CRISPR in Europe: priority becomes just that at the EPO

On April 19, 2017 a preliminary (and non-binding) opinion was issued on the first of the oppositions to the Broad Institute’s granted European patents on CRISPR/Cas9 (European patent number EP 2 771 469).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

More features

Leading European patent litigator to join Carpmaels & Ransford

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

Patent lawyers and judges discuss lofty UPC issues in grand London venue

10x Genomics wins latest round in Parse patent dispute

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

CRISPR in Europe: priority becomes just that at the EPO

More on this story

Editor's picks

Editor's picks

More features